- ►annals.org [PDF] S Faderl, M Talpaz, Z Estrov, HM Kantarjian - Annals of internal medicine, 1999 - Am Coll Physicians Chronic myelogenous leukemia is a myeloproliferative dis- order. It is
characterized by a biphasic or triphasic clinical course in which a benign
chronic phase is followed by transformation into an accelerated and blastic ... Cited by 271 - Related articles - BL Direct - All 6 versions
- ►annals.org HM Kantarjian, TL Smith, S O'Brien, M Beran, … - Annals of Internal Medicine, 1995 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To determine whether a cytogenetic response after interferon- ... Cited by 353 - Related articles - BL Direct - All 7 versions
F Guilhot, C Chastang, M Michallet, A Guerci, … - New England Journal of Medicine, 1997 - content.nejm.org Results The trial was stopped when a sequential analysis showed a benefit of
interferon and cytarabine. A significant improvement in survival was observed in
the interferon–cytarabine group (360 patients) as compared with the ... Cited by 416 - Related articles - BL Direct - All 5 versions
- ►jcojournal.org HM Kantarjian, S O'Brien, TL Smith, MB Rios, J … - Journal of Clinical Oncology, 1999 - jcojournal.org PURPOSE: To evaluate the efficacy of the combination of interferon alpha (IFN- )
and daily low-dose cytarabine (ara-C) in the treatment of patients with early
chronic-phase chronic myelogenous leukemia (CML) (within 1 year of ... Cited by 116 - Related articles - BL Direct - All 7 versions
CL Sawyers… - N Engl J Med, 1999 - com.msu.edu CLINICAL FEATURES CML is a malignant clonal disorder of hemato- poietic stem
cells that results in increases in not only myeloid cells but also erythroid
cells and platelets in peripheral blood and marked myeloid hyperplasia in ... Cited by 785 - Related articles - View as HTML - BL Direct - All 10 versions
HM Kantarjian, D Dixon, MJ Keating, M Talpaz … - CA A Cancer Journal for Clinicians - interscience.wiley.com Determination of the characteristics of accelerated disease in chronic
myelogenous leukemia (CML) helps in individual prognostication, and in the
introduction and analysis of investigative approaches based on risk-benefit ... Cited by 198 - Related articles - All 3 versions
HM Kantarjian, M Talpaz, SO'Brien, TL Smith, … - Clinical Cancer Research, 2002 - AACR We treated 261 patients with Philadelphia chromosome (Ph)-positive chronic
myeloid leukemia (CML) in chronic phase after failure of IFN-α with the Bcr-Abl
tyrosine kinase inhibitor imatinib mesylate (400 mg/day given po) and ... Cited by 106 - Related articles - BL Direct - All 4 versions
- ►bloodjournal.org [PDF] RT Silver, SH Woolf, R Hehlmann, FR … - Blood, 1999 - Am Soc Hematology . Hematology; all rights reserved Copyright 2007 by The American Society of DC
20036. by the American Society of Hematology, 1900 M St, NW, Suite 200,
Washington Blood (print ISSN 0006-4971, online ISSN 1528-0020), is ... Cited by 309 - Related articles - BL Direct - All 9 versions
HM Kantarjian, S O'Brien, P Anderlini, M … - BLOOD-NEW YORK-, 1996 - bloodjournal.hematologylibrary.org . reserved Hematology; all rights Copyright 2007 by The American Society of
Suite 200, Washington DC 20036. semimonthly by the American Society of
Hematology, 1900 M St, NW, Blood (print ISSN 0006-4971, online ISSN ... Cited by 177 - Related articles - View as HTML - BL Direct - All 8 versions
- ►aacrjournals.org [PDF] M Beran, X Cao, Z Estrov, S Jeha, G Jin, S O' … - Clinical cancer research, 1998 - AACR Selective Inhibition of Cell Proliferation and BCR-ABL ... Mioslav Beran,'
Xiaobo Cao, Zeev Estrov, Sima Jeha, Guozhong Jin, Susan O'Brien, Moshe Talpaz,
Ralph B. Arlinghaus, Nicholas B. Lydon, and Hagop Kantarjian Leukemia ... Cited by 153 - Related articles - BL Direct - All 7 versions
